Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 402-408

  Peng, Junping ^a   Gao, Lei ^a   Guo, Junhua ^b   Wang, Ting ^c   Wang, Ling ^c   Yao, Qing ^c   Zhu, Haijun ^c   Jin, Qi ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b Sequenom   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; PROTEIN E6;

ACCURACY; ARTICLE; CONTROLLED STUDY; E6 GENE; EXPLORATORY RESEARCH; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; L1 GENE; MALE; MALE HOMOSEXUAL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; AGED; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84873023030     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01170-12     Document Type: Article

References (40)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
2. Howley PM, Lowy DR. 2007. Papillomaviruses, p 2299-2354. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D. 2011. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377:932-940.
4. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030 -3044.
5. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244 -265.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
7. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.
8. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-527.
9. Gillison ML, Shah KV. 2003. Chapter 9: role of mucosal human papillomavirus in nongenital cancers. J. Natl. Cancer Inst. Monogr. 2003:57- 65.
10. Shah KV. 1997. Human papillomaviruses and anogenital cancers. N. Engl. J. Med. 337:1386 -1388.
11. zur Hausen H. 1989. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49:4677- 4681.
12. Smith JS, Moses S, Hudgens MG, Parker CB, Agot K, Maclean I, Ndinya-Achola JO, Snijders PJ, Meijer CJ, Bailey RC. 2010. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J. Infect. Dis. 201:1677-1685.
13. Molijn A, Kleter B, Quint W, van Doorn LJ. 2005. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32(Suppl 1): S43-S51. doi:10.1016/j.jcv.2004.12.004.
14. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE. 2010. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 11:1160 -1171.
15. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. 2009. Clinical performance of the APTIMAHPVAssay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45(Suppl 1):S55-S61. doi:10.1016/S1386-6532(09)70009-5.
16. Ginocchio CC, Barth D, Zhang F. 2008. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46:1641-1646.
17. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D. 2009. Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MassARRAY). Methods Mol. Biol. 578:307- 343.
18. Peng J, Yang F, Xiong Z, Guo J, Du J, Hu Y, Jin Q. Sensitive and rapid detection of viruses associated with hand foot and mouth disease using multiplexed MALDI-TOF analysis. J. Clin. Virol. [Epub ahead of print.] doi:10.1016/j.jcv.2012.10.020.
19. Ross P, Hall L, Smirnov I, Haff L. 1998. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat. Biotechnol. 16:1347-1351.
20. Syrmis MW, Moser RJ, Whiley DM, Vaska V, Coombs GW, Nissen MD, Sloots TP, Nimmo GR. 2011. Comparison of a multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 17:1804 -1810.
21. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwally A, Khaled H, Kurnit DM. 2005. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc. Natl. Acad. Sci. U. S. A. 102:7683-7688.
22. Basu P, Chandna P, Bamezai RN, Siddiqi M, Saranath D, Lear A, Ratnam S. 2011. MassARRAY spectrometry is more sensitive than Pre- Tect HPV-Proofer and consensus PCR for type-specific detection of highrisk oncogenic human papillomavirus genotypes in cervical cancer. J. Clin. Microbiol. 49:3537-3544.
23. Soderlund-Strand A, Dillner J, Carlson J. 2008. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin. Chem. 54:86 -92.
24. Liu SS, Leung RC, Chan KK, Cheung AN, Ngan HY. 2010. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J. Clin. Microbiol. 48:758 -764.
25. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM. 1994. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169:235-240.
26. Gao L, Zhou F, Li X, Yang Y, Ruan Y, Jin Q. 2010. Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One 5:e15256. doi:10.1371/journal.pone.0015256.
27. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
28. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol. 48:143-149.
29. Vernon SD, Unger ER, Williams D. 2000. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J. Clin. Microbiol. 38:651- 655.
30. Munagala R, Dona MG, Rai SN, Jenson AB, Bala N, Ghim SJ, Gupta RC. 2009. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int. J. Oncol. 34:263-271.
31. zur Hausen H. 2000. Papillomaviruses causing cancer: evasion from hostcell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:690- 698.
32. Ferenczy A, Franco E. 2002. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3:11-16.
33. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. 2008. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am. J. Epidemiol. 168:123-137.
34. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106 -3114.
35. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. 1999. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1633-1638.
36. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249 -257.
37. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13:78-88.
38. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7:453- 459.
39. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 128:927-935.
40. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621- 632.